A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study to Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copaxone in Patients With Relapsing Remitting Multiple Sclerosis

Trial Profile

A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study to Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copaxone in Patients With Relapsing Remitting Multiple Sclerosis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Plovamer (Primary) ; Glatiramer acetate
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms Pathway-1
  • Sponsors EMD Serono; Merck KGaA
  • Most Recent Events

    • 05 Apr 2016 Status changed from completed to discontinued based on sponsor discretion.
    • 24 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Jan 2015 Last checked against United Kingdom Clinical Research record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top